Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2

Status

Completed 2Unknown 1Terminated 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 62Genitourinary 9Breast 6Gastrointestinal 5Gynecologic 4Thoracic 3Head & Neck 3CNS 3Sarcoma 2NET 1Endocrine 1

Conditions

Ovarian Neoplasms 14Uterine Cervical Neoplasms 6Breast Neoplasms 5Melanoma 4Fallopian Tube Neoplasms 4Carcinoma, Ovarian Epithelial 4Vaginal Neoplasms 3Neoplasm Metastasis 3Esophageal Neoplasms 3Stomach Neoplasms 2Penile Neoplasms 2Papillomavirus Infections 2Pancreatic Neoplasms 2Oropharyngeal Neoplasms 2Lung Neoplasms 2Kidney Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Anus Neoplasms 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Recurrence 1Rectal Neoplasms 1Neoplasms 1Mesothelioma 1

Interventions

pembrolizumab 49Nivolumab 22Cyclophosphamide 20fludarabine 13Paclitaxel 9Ipilimumab 9atezolizumab 8aldesleukin 8Specimen Handling 8Interleukin-2 7Carboplatin 7Magnetic Resonance Spectroscopy 6Docetaxel 6Biopsy 6cemiplimab 5fludarabine phosphate 4durvalumab 4Taxes 4Gemcitabine 4Drug Therapy 4spartalizumab 3poly ICLC 3epacadostat 3X-Rays 3Leucovorin 3Injections 3Immunoglobulin G 3Filgrastim 3Cisplatin 3CTLA-4 Antigen 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Melanoma × fludarabine phosphate × Gynecologic × Clear all
NCT02111850 2022-03-29

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
21 enrolled 22 charts
BreastDermatologicGenitourinaryGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Kidney Neoplasms, Melanoma

NCT02096614 2021-06-18

Investigator Initiated Phase 1 Study of TBI-1201

Mie University

Phase 1 Completed
18 enrolled
DermatologicGastrointestinalGynecologicHead & Neck

Esophageal Neoplasms, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms

NCT02153905 2019-06-17

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
3 enrolled 14 charts
BreastDermatologicGenitourinaryGynecologic

Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Kidney Neoplasms, Melanoma, Neoplasm Metastasis

NCT02366546 2018-10-24

Investigator Initiated Phase 1 Study of TBI-1301

Mie University

Phase 1 Unknown
9 enrolled
DermatologicGastrointestinalGynecologicHead & NeckSarcoma

Esophageal Neoplasms, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Synovial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡